Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 15/20 | 0.44 |
| ▸ | CNR2 | P34972 | 14/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26047672 | 0.76 | HPGD (0.47) | MEN1HPGDKMT2ACNR1CNR2 | |
| SCHEMBL25850543 | 0.74 | CNR1 (0.44) | CNR1CNR2 | |
| SCHEMBL25849004 | 0.72 | NPC1 (0.33) | MEN1KMT2ACNR1CNR2MAPT | |
| SCHEMBL13498639 | 0.71 | TSHR (0.71) | MEN1HPGDKMT2ACNR1SMN1; SMN2 | |
| SCHEMBL26721862 | 0.70 | NPC1 (0.52) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL25843185 | 0.69 | FAAH (0.53) | MEN1KMT2ACNR1CNR2 | |
| SCHEMBL25835758 | 0.69 | CNR1 (0.51) | MEN1KMT2ACNR1CNR2MAPT | |
| SCHEMBL26035275 | 0.67 | CNR1 (0.39) | MEN1KMT2ACNR1CNR2MAPT | |
| SCHEMBL26035258 | 0.67 | CNR1 (0.38) | MEN1KMT2ACNR1CNR2MAPT | |
| SCHEMBL25548847 | 0.66 | CASP2 (0.47) | MEN1KMT2ACNR1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | MEN1 4753/4885HPGD 2974/4885KMT2A 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.